Warrant reviews your marketing against 3,388 rules from 1,267 regulators across 11 countries. Every flag is cited to its source. Search the full library below.
Coverage includes the FTC, FDA, CFPB, SEC, FINRA, NCUA, FDIC, OCC, NAIC, and regulators from all 50 U.S. states, the European Union, Canada, and more.
Regulation guides
21 CFR Part 201 requires OTC drug labels to carry a standardized Drug Facts panel and prescription labels to carry 'Rx only', with label claims consistent with approved labeling.
21 CFR Part 201 (incl. 201.66, 201.100); 21 U.S.C. 353(b)(4)
OTC drug marketing to Alaska consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
AS 45.50.471(b)(4), (7), (12), (48); 21 C.F.R. § 201.66(c)
OTC drug marketing to Alabama consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
Ala. Code 8-19-5; 21 U.S.C. 352; 21 CFR 201.66
OTC drug marketing to Arkansas consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
Ark. Code § 4-88-107(a)(1), (a)(10); 21 C.F.R. § 201.66(c)
OTC drug marketing to Arizona consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
A.R.S. § 44-1522(A), (C); 21 C.F.R. § 201.66(c)
Alaska's pharmacy practice law, enforced by the Alaska Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Alaska pharmacy ads.
AS 08.80.261(a)(2), (3), (9)-(11); AS 08.80.420
Arizona's pharmacy practice law, enforced by the Arizona State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Arizona pharmacy ads.
A.R.S. § 32-1901.01(A)(22), (A)(26), (B)(11)
California's Sherman Law bars false or misleading drug advertising; OTC drug ads must stay within the product's labeled OTC uses and must not overstate efficacy or regulatory status.
Cal. Health & Safety Code §§ 110390, 110403, 110405
OTC drug marketing to Colorado consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
21 U.S.C. § 352(a); 15 U.S.C. § 52(a); 21 CFR § 201.66(c); C.R.S. § 6-1-105(1)(e)
Connecticut's Food, Drug and Cosmetic Act and CUTPA bar false or misleading OTC drug claims; packaging must carry FDA Drug Facts labeling.
Conn. Gen. Stat. §§ 21a-106, 21a-113, 21a-114; 42-110b(a); 21 CFR § 201.66(c)
California's pharmacy practice law, enforced by the California State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in California pharmacy ads.
Cal. Bus. & Prof. Code §§ 651, 4059, 17500
Colorado's pharmacy practice law, enforced by the Colorado State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Colorado pharmacy ads.
C.R.S. § 12-280-126(1)(h); C.R.S. § 12-280-123(1)(a)
Manufacturer representatives marketing a prescription drug to Colorado prescribers must provide the drug's wholesale acquisition cost and the names of up to three generic drugs in the same therapeutic class where available; only written materials can be checked.
C.R.S. § 12-280-308 (HB19-1131)
No-cost vaccine coverage under private plans and Medicaid depends on ACIP recommendations adopted by CDC, generally applies in network, and does not reach grandfathered plans, so coverage claims must be qualified and kept current.
42 U.S.C. 300gg-13(a)(2); 45 CFR 147.130; 45 CFR 147.140
Connecticut pharmacy ads must not misstate drug efficacy or safety, call compounded drugs FDA-approved, make unqualified price claims, offer Rx incentives without federal program exclusions, or offer Rx drugs without a prescription.
Conn. Gen. Stat. §§ 21a-113, 21a-114, 42-110b(a)
Pharmaceutical representatives marketing a legend drug to Connecticut prescribers or pharmacists are reported to be required to disclose the drug's list price in writing; the statute and any additional disclosure items need verification before the rule is enabled.
Conn. Gen. Stat. § 21a-70j(1)
OTC drug marketing to Delaware consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
6 Del. C. § 2513(a); 15 U.S.C. § 52(a); 21 U.S.C. § 352(a); 21 C.F.R. § 201.66(c)
District of Columbia pharmacy ads must not misstate drug efficacy or safety, call compounded drugs FDA-approved, make unqualified price claims, offer Rx incentives without federal program exclusions, or offer Rx drugs without a prescription.
21 U.S.C. § 352(bb); D.C. Code § 28-3904(a)(1), (a)(2), (a)(5), (a)(7), (a)(8); 42 U.S.C. § 1320a-7a(a)(5); 42 U.S.C. § 1320a-7b(b)(2)(B); 21 U.S.C. § 353(b)(1)
Advertising prescription-only medicines to the EU general public is prohibited; unbranded disease awareness and materials for health professionals are allowed.
Directive 2001/83/EC Arts 86, 88(1)(a)
Public advertising of non-prescription medicines in the EU must identify the ad and the medicine, name it, invite the reader to read the leaflet, and avoid the prohibited claims in Art. 90.
Directive 2001/83/EC Arts. 87, 89(1), 90 (as amended by Directive 2004/27/EC)
Animal drug ads must be truthful and balanced; prescription animal drug ads, including those aimed at owners, must present major risks and must not imply the drug is available without a veterinarian's prescription.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e); 21 CFR 201.105(b)(1)
Sunscreen, acne and dandruff products must use FDA-permitted claim terms and stay within monograph uses; full Drug Facts statements apply to labels, not to every ad.
21 CFR 201.327; OTC Monographs M020, M006, M032 (FD&C 505G)
DTC TV and radio prescription drug ads must present the major risk statement in consumer-friendly language, at comparable audio quality, with concurrent on-screen text on TV and without distracting elements.
21 CFR 202.1(e)(1)(i)-(ii)
FDA recommends that consumer-directed prescription drug promotion stating efficacy or risk numbers give absolute frequencies for the drug and control groups, use consistent formats, and avoid relative-only figures that overstate benefit.
21 U.S.C. 352(n); 21 CFR 202.1(e)(5)-(6); FDA Quantitative Efficacy and Risk DTC Guidance (2023)
Holds Rx drug and restricted device companies to FDA fair-balance and claim limits in influencer, paid-partner and brand-amplified user content.
21 U.S.C. 352(n), (bb); 21 CFR 202.1(e)(5)-(6)
Requires company-owned digital promotion of Rx drugs and restricted devices to give the most serious risks alongside benefits, the established name, and access to full prescribing information.
21 U.S.C. 352(n); 21 CFR 202.1(b)(1), (e)(1), (e)(5)-(6); FDA Character Space Draft Guidance (2014)
Requires consumer TV, radio and video prescription drug ads to present the major statement of risks clearly, conspicuously and neutrally and to provide a brief summary or adequate provision.
21 CFR 202.1(e)(1) (as amended, 88 FR 80958, compliance Nov. 20, 2024)
Requires DTC Rx ads to present the major risk statement clearly, conspicuously and neutrally, to provide adequate provision for full prescribing information in broadcast, and to include a brief summary in print.
21 U.S.C. 352(n); 21 CFR 202.1(e)(1), (e)(6)
Unbranded disease-awareness pieces are outside the risk-disclosure rules only while they do not identify or suggest a specific product; brand cues, single-product category claims or a direct bridge to branded content make them promotion.
21 CFR 202.1(e), (l)(2); FDA Help-Seeking Draft Guidance (2004)
On character-limited platforms (paid search, short posts, SMS), a prescription drug benefit claim should be accompanied in the same unit by the established name, the most serious risks and a direct link to complete risk information, or the claim should not be made there.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e); FDA Character Space Draft Guidance (2014)
Requires OTC drug labels to carry a complete Drug Facts panel in the prescribed order and format with ingredient-specific warnings.
21 CFR 201.66; 21 U.S.C. 352
OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph.
21 CFR 358 (deemed final OTC monograph orders, FD&C Act 505G)
Data in promotion that are not in the labeling, including real-world evidence, must be consistent with the approved conditions of use and be presented with the study design, limitations and context needed to avoid misleading the reader.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(6); FDA CFL Q&A Guidance (2018)
Requires prescription drug promotion to healthcare professionals to have fair balance, a brief summary or full Prescribing Information, on-label claims and substantiated comparisons.
21 CFR 202.1(e); FD&C Act § 502(n)
Social media promotion that names a prescription drug or restricted device and makes a benefit claim must present the most serious risks in the same post with balanced prominence and a link to full risk information.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e); FDA Character Space Draft Guidance (2014)
Homeopathic products are drugs; marketing must not imply FDA approval, must not promote them for serious diseases, and efficacy claims must be scientifically supported or clearly qualified as based only on homeopathic theory.
21 U.S.C. 321(g)(1), 352; FDA Guidance: Homeopathic Drug Products (Dec 2022); FTC Enforcement Policy Statement on OTC Homeopathic Drug Claims (2016)
Rx drug ads must present risks with fair balance, include a brief summary or major statement, keep broadcast risk statements clear, conspicuous and neutral, stay within the label, and compounded-drug ads must not imply FDA approval or brand equivalence.
21 U.S.C. 352(a), (n), (bb); 21 CFR 202.1(e)(1), (e)(5), (e)(6), (e)(7)
Promotion of drugs with a boxed warning must convey the boxed-warning risk with prominence comparable to benefit claims, and reminder ads are not permitted for these drugs.
21 CFR 202.1(e)(1), (e)(2)(i), (e)(5)(ii), (e)(7)(viii); 21 CFR 201.57(c)(1); 21 U.S.C. 352(n)
Prescription drug ads that name a drug and its use must present risk information with prominence comparable to benefit claims and must not overstate efficacy or safety.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(1), (e)(5)(ii), (e)(6), (e)(7)
Disease-awareness ads from drug firms may discuss a condition and urge a doctor visit but must not name, cue or point to a specific drug; if they do, they become product ads needing risk information.
21 CFR 202.1; 21 U.S.C. 352(n); FDA Draft Guidance, Help-Seeking and Other Disease Awareness Communications (Jan. 2004) secs. III.A, IV
Drug firms may not promote prescription drugs for unapproved uses; scientific information on unapproved uses may go to HCPs only if separate from promotion and accompanied by the disclosures in FDA's 2025 guidance.
21 U.S.C. 352(a), (f), (n); 21 CFR 202.1(e)(4)(i)(a), (e)(6)(i), (e)(6)(xi); 21 CFR 201.128; FDA SIUU Q&A Guidance (Jan. 2025) sec. V, Q2-Q5
Patient testimonials for prescription drugs must not convey atypical or off-label results or downplay risk, and product-claim testimonials need risk information.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(1), (e)(4)(i)(a), (e)(5)(ii), (e)(6)
Prescription drug promotion must not depict or target age groups outside the approved indication and must include labeled age-specific risks when targeting that group.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(5)(ii), (e)(6)(i), (e)(6)(xix), (e)(7)(x); 21 CFR 201.57(c)(9)(iv)-(v)
Reminder ads may name a prescription drug with limited facts but may not state or imply its use or make claims, and are not allowed for drugs with boxed warnings.
21 CFR 202.1(e)(2)(i); 21 CFR 201.100(f)
Social and character-limited posts that name a prescription drug and its benefit must state the most serious risks in the post and link to complete risk information.
21 CFR 202.1(e)(1), (e)(5)(ii), (e)(6)(i), (e)(6)(iv); 21 U.S.C. 352(a), (n)
OTC drug labels must carry a Drug Facts panel in the 21 CFR 201.66 format with the ingredient-specific warnings, such as the acetaminophen liver warning and aspirin Reye's syndrome warning.
21 CFR 201.66; 21 CFR 201.63, 201.314(h), 201.326
Limits OTC monograph drug claims (sunscreens, acne, antiperspirants) to permitted indications and terms, bans terms such as 'sunblock' and 'waterproof', and requires Drug Facts on labeling.
21 U.S.C. 355h; 21 CFR 201.66, 201.327; former 21 CFR 333.310, 333.350, 350.50
Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion.
21 U.S.C. 352(a), (f); 21 CFR 202.1; FDA SIUU Q&A Guidance (Jan. 2025)
Prescription drug promotion must stay within the approved indication; information on unapproved uses may be shared only separately from promotion under FDA's safe-harbor guidance or in reply to unsolicited requests.
21 U.S.C. 331(a), 352(a)(1), 352(f); 21 CFR 201.128; 21 CFR 202.1(e)(6)(i), (xi)
Requires prescription drug advertising in all channels to present risks with fair balance, include a brief summary or equivalent, and avoid overstated, off-label or unsupported claims.
21 CFR 202.1(e); FD&C Act § 502(n)
Consumer-directed TV, radio and streaming ads for prescription drugs must include a major statement of the major risks presented in a clear, conspicuous and neutral manner (consumer-friendly language, audio as clear as the rest of the ad, concurrent text on TV, no distractions), plus adequate provision for full labeling.
21 CFR 202.1(e)(1); 21 U.S.C. 352(n)
Consumer-directed published and digital prescription drug product-claim ads must include a true statement of side effects, contraindications and effectiveness in brief summary form.
21 U.S.C. 352(n); 21 CFR 202.1(e)(1), (e)(3)(iii), (e)(5)-(6)
Claims that a prescription product is safer, more effective, the only or the first compared with other products require substantial evidence, normally head-to-head data, and must be accurately qualified; compounded drugs must not be marketed as FDA-approved or equivalent to a brand.
21 U.S.C. 352(a), (n), (bb); 21 CFR 202.1(e)(5), (e)(6)(ii)
Promotion may not represent or suggest that a prescription drug or biologic is more effective, more durable or useful in a broader range of conditions than substantial evidence shows.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(5)-(6)
Promotion must present risk information with prominence and readability reasonably comparable to the benefit claims and must not bury, shrink or visually minimize risks.
21 CFR 202.1(e)(5)(ii), (e)(7)(vii)-(viii); 21 U.S.C. 352(n)
Wherever the proprietary name is featured, the established (generic) name must accompany it in direct conjunction, in type at least half as large and of comparable prominence.
21 CFR 202.1(b)(1)-(3); 21 CFR 201.10(g); FDA Product Name Placement Guidance (2017)
Promotion may not represent or suggest that a prescription drug is safer or has fewer or less serious risks than shown in its labeling, including by minimizing warnings and precautions.
21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(5)-(7)
Prescription drug and biologic promotion may not recommend or suggest any population, dose, regimen, timing or combination that is not in the approved labeling.
21 U.S.C. 352(a), (f), (n); 21 CFR 202.1(e)(4), (e)(5), (e)(6)
Promotional labeling for a prescription product that makes claims about it must be accompanied by the full Prescribing Information; digital pieces satisfy this with a clearly labeled, working link.
21 CFR 201.100(d); 21 CFR 202.1(l)(2); 21 U.S.C. 352(f)
A reminder piece may skip risk information only if it calls attention to the product name with permitted factual items and no representations, and reminders are not available for drugs with a boxed warning.
21 CFR 202.1(e)(2)(i); 21 CFR 201.100(f)
Firm communications to HCPs about unapproved uses must be scientifically sound, kept separate from promotion, free of persuasive elements and accompanied by disclosures: the use is unapproved, the approved uses and labeling, study design and limitations, conflicting data and financial ties.
FDA SIUU Communications Q&A Guidance (Jan. 2025); 21 U.S.C. 352(a)
Rx drug posts by brands and paid creators must include the drug names, indication, the most serious risks and a link to full risk information, and sponsored posts need a clear material-connection disclosure under FTC rules.
21 U.S.C. 352(a), (n); 21 CFR 202.1; 16 CFR 255.5; FDA Character Space Draft Guidance (2014)
Published consumer-directed prescription drug ads must include, in conspicuous text, the statutory statement encouraging consumers to report negative side effects to FDA via MedWatch.
21 U.S.C. 352(n) (FD&C Act 502(n), FDAAA 2007 s.906)
Florida's Drug and Cosmetic Act bars false or misleading drug advertising; OTC drug ads must stay within labeled uses and accurately state strength and regulatory status.
Fla. Stat. ch. 499 (Florida Drug and Cosmetic Act), incl. 499.0054
Sunscreen labels and ads in Florida must follow FDA sunscreen rules: no 'sunblock', 'waterproof' or 'sweatproof' claims, stated water-resistance times, and skin cancer claims only for broad spectrum SPF 15+ products.
21 CFR 201.327(a)(2), (c)(2)-(3), (d)(2), (e)(3)-(4), (g); Fla. Stat. § 499.007(1)
Ads for OTC homeopathic drugs that make efficacy claims must convey that there is no scientific evidence the product works and that the claims rest only on 1700s homeopathic theories most modern experts reject.
FTC Act, 15 U.S.C. 45, 52; FTC Enforcement Policy Statement on Marketing Claims for OTC Homeopathic Drugs (2016)
Homeopathic ad disclosures must be clear, conspicuous and close to the claim, and visuals or endorsements must not imply scientific or medical validation that contradicts them.
FTC Act, 15 U.S.C. 45, 52; FTC Enforcement Policy Statement on Marketing Claims for OTC Homeopathic Drugs (2016)
OTC drug ads must not mislead through testimonials, endorsements or safety claims; atypical results need generally expected results disclosed, and endorser connections must be disclosed.
FTC Act, 15 U.S.C. 45, 52; 16 CFR Part 255
Efficacy, speed and comparative claims for OTC drugs require competent and reliable scientific evidence matching the strength of the claim.
FTC Act, 15 U.S.C. 45, 52; FTC Policy Statement Regarding Advertising Substantiation (1984)
Florida's pharmacy practice law, enforced by the Florida Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Florida pharmacy ads.
Fla. Stat. ch. 465; Fla. Admin. Code ch. 64B16
French medicine ads need an ANSM visa (GP for the public, PM for health professionals); prescription-only medicines cannot be advertised to the public and claims must be on-label.
Code de la santé publique Art. L.5122-6 (al. 1 and final al.); Art. L.5122-8 (al. 1); Art. L.5122-9 (al. 1); Art. L.5122-2
OTC drug marketing to Georgia consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
O.C.G.A. § 10-1-393(a), (b)(2), (b)(5), (b)(7); O.C.G.A. § 26-3-8(a)(1); 21 CFR 201.66(c)
Georgia's pharmacy practice law, enforced by the Georgia Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Georgia pharmacy ads.
O.C.G.A. § 10-1-393(a), (b)(2), (b)(5), (b)(7), (b)(9)
OTC drug marketing to Hawaii consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
HRS §§ 328-15(1), 328-20(a); HRS § 480-2(a); 21 CFR 201.66(c)
Hawaii's pharmacy practice law, enforced by the Hawaii Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Hawaii pharmacy ads.
Haw. Admin. R. §§ 16-95-101, 16-95-102, 16-95-103, 16-95-110(a)(13)
OTC drug ads directed to Iowa consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
15 U.S.C. § 52(a), (b); Iowa Code § 126.16(1), (2); 21 CFR 201.66(c)(4), (c)(5), (c)(6)
OTC drug marketing to Idaho consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
Idaho Code § 48-603(2), (5), (7), (17); 21 CFR 201.66(c)
OTC drug marketing to Illinois consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
410 ILCS 620/3.5, 15, 20; 815 ILCS 505/2; 21 CFR 201.66
OTC drug marketing to Indiana consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
IC 24-5-0.5-3; 21 CFR 201.66
Idaho's pharmacy practice law, enforced by the Idaho Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Idaho pharmacy ads.
Idaho Code § 48-603(2)-(3), (5), (17)
Illinois pharmacy ads must not misstate drug efficacy or safety, call compounded drugs FDA-approved, make unqualified price claims, offer Rx incentives without federal program exclusions, or offer Rx drugs without a prescription.
225 ILCS 85/30(a)(29); 815 ILCS 505/2
Indiana's pharmacy practice law, enforced by the Indiana State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Indiana pharmacy ads.
IC 24-5-0.5-3(a), (b)(1), (b)(2), (b)(6); 21 U.S.C. 353(b)(1); 42 U.S.C. 1320a-7a(a)(5), 1320a-7b(b); IC 25-26-13-29
Social content by creators, patients or HCPs who are paid by or partnered with a manufacturer or seller must clearly disclose the connection, and personal-experience claims must not imply results beyond the labeling or typical experience.
16 CFR 255.2, 255.3, 255.5; 15 U.S.C. 45; 21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(6)
Iowa's pharmacy practice law, enforced by the Iowa Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Iowa pharmacy ads.
Iowa Code 155A.15(2)(b); 155A.23(1)(q); 714.16(2)(a); 21 U.S.C. 353(b)(1); 42 U.S.C. 1320a-7a(a)(5)
Italy bans public advertising of prescription medicines and requires consumer ads for non-prescription medicines to carry minimum information, a leaflet invitation and Ministry of Health authorization.
D.Lgs. 24 aprile 2006, n. 219, artt. 114-118
OTC drug marketing to Kansas consumers must keep claims within label or monograph uses, avoid absolute or unsupported comparative claims, and carry a Drug Facts panel on labels; ads need not repeat Drug Facts.
K.S.A. 50-626(b)(1)(A), (F), (G), (b)(2); 21 CFR 201.66(c)
OTC drug ads directed to Kentucky consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
15 U.S.C. 45(a)(1); 15 U.S.C. 52(a); 21 U.S.C. 352(a)(1), (f); 21 U.S.C. 355h; KRS 217.105(1); KRS 217.175(5); KRS 217.065(1), (6)(a)-(b)
Kansas's pharmacy practice law, enforced by the Kansas State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Kansas pharmacy ads.
K.S.A. 50-626(b); 21 U.S.C. 353(b)(1); 42 U.S.C. 1320a-7a(a)(5), 1320a-7b(b)
Kentucky's pharmacy practice law, enforced by the Kentucky Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Kentucky pharmacy ads.
KRS 315.121(2)(a), (f); 21 U.S.C. 353(b)(1); 42 U.S.C. 1320a-7a(a)(5), 1320a-7b(b)
OTC drug ads directed to Louisiana consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
15 U.S.C. 45(a)(1); 15 U.S.C. 52(a); 21 U.S.C. 352(a)(1), (f); 21 U.S.C. 355h; La. R.S. 40:625(A), (C); La. R.S. 40:617(A)(1)-(2); 21 CFR 201.66(c)(4)-(6)
Louisiana's pharmacy practice law, enforced by the Louisiana Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Louisiana pharmacy ads.
La. R.S. 37:1241(A)(19); LAC 46:LIII.1115(A); FD&C Act §§ 503A, 503B; 42 U.S.C. 1320a-7b(b); 42 U.S.C. 1320a-7a(a)(5)
OTC drug ads directed to Massachusetts consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
15 U.S.C. 45(a)(1); 15 U.S.C. 52(a); 21 U.S.C. 352(a)(1), (f); 21 U.S.C. 355h; Massachusetts state basis not verified
Maryland and federal law bar false or misleading OTC drug advertising; ads must not claim cures, FDA approval or prescription strength, or make absolute safety claims beyond the product's labeled uses.
Md. Code, Health-Gen. Title 21, Subtitle 2; Md. Code, Com. Law Sec. 13-301; 21 CFR Part 330; FTC Act Secs. 5, 12, 15
OTC drug ads directed to Maine consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
15 U.S.C. 45(a)(1); 15 U.S.C. 52(a); 21 U.S.C. 352(a)(1), (f); 21 U.S.C. 355h; 5 M.R.S. Sec. 207
OTC drug ads directed to Minnesota consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
15 U.S.C. 45(a)(1); 15 U.S.C. 52(a); 21 U.S.C. 352(a)(1), (f); 21 U.S.C. 355h; Minn. Stat. § 151.36(1), (3)-(4)
OTC drug ads directed to Missouri consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
15 U.S.C. 45(a)(1); 15 U.S.C. 52(a); 21 U.S.C. 352(a)(1), (f); 21 U.S.C. 355h; RSMo 196.120
Mississippi and federal law bar false or misleading OTC drug ads; claims must stay within labeled symptom-relief uses without cure, absolute safety or unsupported superiority claims.
Miss. Code Ann. § 75-24-5(2); 21 C.F.R. § 201.66
OTC drug ads directed to Montana consumers must not make false or misleading use, efficacy or safety claims or promote uses outside the label; Drug Facts content is checked only on packaging and labels.
15 U.S.C. 45(a)(1); 15 U.S.C. 52(a); 21 U.S.C. 352(a)(1), (f); 21 U.S.C. 355h; Mont. Code Ann. 50-31-303(1); Mont. Code Ann. 50-31-306(1)(a), (1)(f)
Maine's pharmacy practice law, enforced by the Maine Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Maine pharmacy ads.
32 M.R.S. Sec. 13782; 21 U.S.C. 352(a)(1); 21 U.S.C. 353a, 353b (FD&C Act Secs. 503A, 503B); 42 U.S.C. 1320a-7a(a)(5); 42 U.S.C. 1320a-7b(b); 5 M.R.S. Sec. 207
Manufacturer copay coupons and savings offers can implicate the federal Anti-Kickback Statute if used by Medicare, Medicaid or other government program beneficiaries, so offers must clearly exclude those beneficiaries and not target them.
42 U.S.C. 1320a-7b(b), (f); HHS-OIG Special Advisory Bulletin, Pharmaceutical Manufacturer Copayment Coupons (Sept. 2014)
Maryland's pharmacy practice law, enforced by the Maryland Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Maryland pharmacy ads.
Md. Code Ann., Health Occ. Title 12
Massachusetts pharmacy marketing must not misrepresent compounded drugs as FDA-approved, mislead on drug prices or efficacy, or offer copay waivers and coupons to federal health program beneficiaries.
247 CMR 9.01(9); M.G.L. c. 93A, § 2(a); 42 U.S.C. § 1320a-7a(a)(5), (i)(6)
Under the Inflation Reduction Act, Part D plans may not charge cost sharing for ACIP-recommended adult vaccines, so '$0 with Medicare' claims are true only for Part D or MA-PD enrollees in the recommended group, and Part D vaccines such as shingles and RSV are not Part B benefits.
42 U.S.C. 1395w-102(b)(8), (c)(5); 15 U.S.C. 45(a)(1)
Michigan's pharmacy practice law, enforced by the Michigan Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Michigan pharmacy ads.
MCL 333.16221(d)(i); MCL 445.903(1); 42 U.S.C. § 1320a-7a(a)(5)
Minnesota's pharmacy practice law, enforced by the Minnesota Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Minnesota pharmacy ads.
Minn. Stat. § 151.071, subd. 2(9); 325F.67; 325D.44; 42 U.S.C. § 1320a-7a(a)(5)
Mississippi's pharmacy practice law, enforced by the Mississippi Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Mississippi pharmacy ads.
Miss. Code Ann. § 75-24-5(2); Miss. Code Ann. § 73-21-97; 42 U.S.C. § 1320a-7a(a)(5)
Missouri's pharmacy practice law, enforced by the Missouri State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Missouri pharmacy ads.
Mo. Rev. Stat. § 338.055.2(14); 21 U.S.C. § 353(b)(1); 42 U.S.C. § 1320a-7b(b)
Montana's pharmacy practice law, enforced by the Montana Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Montana pharmacy ads.
21 U.S.C. § 353(b)(1); 42 U.S.C. § 1320a-7b(b); Mont. Code Ann. § 30-14-103
OTC drug ads seen by North Carolina consumers must make only truthful, substantiated claims within labeled OTC indications; Drug Facts, warnings and directions are checked only on packaging and labeling.
N.C.G.S. § 106-138; 15 U.S.C. 52, 55; 21 CFR 201.66
North Dakota and federal law bar false or misleading OTC drug ads, including implied prescription strength, cure or guarantee claims and misstated ingredients or uses.
N.D.C.C. §§ 19-02.1-02(5), 19-02.1-19; 21 CFR 201.66
OTC drug advertising to Nebraska consumers must not make deceptive cure, safety, efficacy or FDA-approval claims or promote uses beyond the label.
15 U.S.C. § 52; 21 U.S.C. § 352(a); 21 CFR 330.1(c)-(d), 201.66(c); Neb. Rev. Stat. §§ 59-1602, 87-302
OTC drug ads seen by New Hampshire consumers must make only truthful, substantiated claims within labeled OTC indications; Drug Facts, warnings and directions are checked only on packaging and labeling.
15 U.S.C. § 52; 21 CFR 330.1, 201.66; N.H. Rev. Stat. Ann. § 358-A:2
New Jersey and federal law bar false or misleading OTC drug ads, including cure claims, implied prescription strength, guaranteed or instant relief and misleading endorsements.
15 U.S.C. § 52; 21 CFR 330.1, 201.66; 16 CFR 255; N.J.S.A. 56:8-2
OTC drug ads seen by New Mexico consumers must make only truthful, substantiated claims within labeled OTC indications; Drug Facts, warnings and directions are checked only on packaging and labeling.
NMSA 1978 § 26-1-12; 15 U.S.C. 52, 55; 21 CFR 201.66(c); 21 CFR 101.93
Nevada and federal law bar false or misleading OTC drug ads; claims must stay within labeled uses without cure, universal-age safety or absolute claims, and packaging must carry Drug Facts.
15 U.S.C. § 52; 21 CFR 330.1, 201.66; NRS 598.0915(2), (5)
New York and federal law bar false or misleading OTC drug ads, including cure, prescription-equivalence, unlabeled-use and misleading safety claims.
N.Y. Educ. Law § 6815(2); N.Y. GBL §§ 349, 350, 350-a; 15 U.S.C. 52, 55; 21 CFR 201.66
Nebraska's pharmacy practice law, enforced by the Nebraska Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Nebraska pharmacy ads.
Neb. Rev. Stat. §§ 59-1602, 87-302; 21 U.S.C. § 353(b)(1); 42 U.S.C. § 1320a-7b(b)
Nevada's pharmacy practice law, enforced by the Nevada State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Nevada pharmacy ads.
NRS 639.263; NRS 639.264(1); NRS 454.221(1); NRS 598.0915(2), (3)
New Hampshire's pharmacy practice law, enforced by the New Hampshire Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in New Hampshire pharmacy ads.
N.H. Rev. Stat. Ann. § 358-A:2; 21 U.S.C. § 353(b)(1); 42 U.S.C. § 1320a-7b(b)
New Jersey's pharmacy practice law, enforced by the New Jersey Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in New Jersey pharmacy ads.
N.J.S.A. 56:8-2; 21 U.S.C. § 353(b)(1); 42 U.S.C. § 1320a-7b(b)
New Mexico's pharmacy practice law, enforced by the New Mexico Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in New Mexico pharmacy ads.
NMSA 1978 §61-11-1 et seq.; 16.19 NMAC
New York's pharmacy practice law, enforced by the New York State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in New York pharmacy ads.
N.Y. Educ. Law § 6810(1); N.Y. Educ. Law § 6811(12), (13); N.Y. Gen. Bus. Law § 349(a); federal: 21 U.S.C. §§ 353a, 353b (FD&C Act §§ 503A, 503B); 42 U.S.C. §§ 1320a-7b(b), 1320a-7a(a)(5)
North Carolina's pharmacy practice law, enforced by the North Carolina Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in North Carolina pharmacy ads.
N.C.G.S. §§ 106-138, 75-1.1
North Dakota's pharmacy practice law, enforced by the North Dakota State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in North Dakota pharmacy ads.
N.D.C.C. § 43-15-10(1)(b), (1)(i); federal: FD&C Act §§ 503A/503B; 42 U.S.C. §§ 1320a-7b(b), 1320a-7a(a)(5)
Ohio and federal law bar false or misleading OTC drug ads, including cure, implied prescription, off-label and guaranteed claims.
R.C. 3715.68; R.C. 1345.02(B); 15 U.S.C. 52, 55; 21 CFR 201.66
Oklahoma and federal law bar false or misleading OTC drug ads, including cure, unsourced superiority, off-label and guaranteed claims.
15 U.S.C. § 52; 21 U.S.C. § 352(a); 21 C.F.R. § 201.66
Oregon and federal law bar false or misleading OTC drug ads, including cure claims, unsourced superlatives, unsupported professional endorsements and off-label uses.
ORS 646.608; 15 U.S.C. § 52; 21 C.F.R. § 201.66
Ohio's pharmacy practice law, enforced by the Ohio State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Ohio pharmacy ads.
21 U.S.C. §§ 352-353; 42 U.S.C. §§ 1320a-7a, 1320a-7b
Oklahoma's pharmacy practice law, enforced by the Oklahoma State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Oklahoma pharmacy ads.
59 O.S. § 353 et seq.; 21 U.S.C. §§ 352-353; 42 U.S.C. §§ 1320a-7a, 1320a-7b; 15 O.S. § 753
Oregon's pharmacy practice law, enforced by the Oregon State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Oregon pharmacy ads.
ORS 689.405(1)(a); OAR 855-006-0020; federal: FD&C Act §§ 503A/503B; 42 U.S.C. §§ 1320a-7b(b), 1320a-7a(a)(5)
Pennsylvania and federal law bar false or misleading OTC drug ads, including cure claims, unsourced pharmacist endorsements, absolute superlatives and off-label uses.
21 C.F.R. pt. 330; 21 C.F.R. § 201.66; 73 P.S. § 201-2(4); 15 U.S.C. § 52
Pennsylvania's pharmacy practice law, enforced by the Pennsylvania State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Pennsylvania pharmacy ads.
63 P.S. § 390-5(a)(9); 21 U.S.C. §§ 352, 353; 42 U.S.C. §§ 1320a-7a, 1320a-7b
OTC drug ads seen by Rhode Island consumers must make only truthful, substantiated claims within labeled OTC indications; Drug Facts, warnings and directions are checked only on packaging and labeling.
FTC Act Secs. 5, 12 (15 U.S.C. 45, 52); 21 U.S.C. 352; state Board of Pharmacy basis unverified
Rhode Island's pharmacy practice law, enforced by the Rhode Island Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Rhode Island pharmacy ads.
R.I. Gen. Laws ch. 5-19.1
Statements about what a patient will pay or save for a prescription drug ($0, free, covered, savings) must be accurate and qualified by who is eligible, the coverage involved, limits and the basis for the figure.
21 U.S.C. 352(a)(1); 15 U.S.C. 45(a)
OTC drug ads seen by South Carolina consumers must make only truthful, substantiated claims within labeled OTC indications; Drug Facts, warnings and directions are checked only on packaging and labeling.
15 U.S.C. 45(a)(1), 52(a); 21 U.S.C. 352; S.C. Code § 39-23-40(a), (f); S.C. Code § 39-23-20
South Dakota and federal law bar false or misleading OTC drug ads, including cure or guarantee claims, off-label conditions, downplayed side effects and unsourced clinical claims.
SDCL § 37-24-6(1); 15 U.S.C. §§ 45, 52; 21 CFR 201.66(c)
South Carolina's pharmacy practice law, enforced by the South Carolina Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in South Carolina pharmacy ads.
S.C. Code Ann. Title 40, ch. 43
South Dakota's pharmacy practice law, enforced by the South Dakota Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in South Dakota pharmacy ads.
SDCL §§ 36-11-20(4), 37-24-6(1); 42 U.S.C. § 1320a-7a(a)(5)
Tennessee and federal law bar false or misleading OTC drug ads, including disease cure claims, risk denial, misleading ingredient comparisons and off-label efficacy claims.
Tenn. Code Ann. § 47-18-104(b); 15 U.S.C. § 52; 21 CFR 201.66
Texas and federal law bar false or misleading OTC drug ads, including disease claims, misstated ingredients, prescription-superiority claims and blanket child-safety claims; packaging must carry Drug Facts.
Tex. Bus. & Com. Code § 17.46(b)(5); Tex. Health & Safety Code § 431.021; 21 CFR 201.66
Tennessee's pharmacy practice law, enforced by the Tennessee Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Tennessee pharmacy ads.
Tenn. Code Ann. §§ 63-10-309, 47-18-104(b)
Texas's pharmacy practice law, enforced by the Texas State Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Texas pharmacy ads.
Tex. Occ. Code § 565.001(a)
UK law bars advertising prescription-only medicines to the public and requires medicine ads to stay on-licence, with required content for OTC ads.
Human Medicines Regulations 2012 Part 14; Sch 30
UK law bans advertising prescription-only medicines to the public and requires all medicine ads to match the product's authorisation, with label-reading invitations on consumer OTC ads.
Human Medicines Regulations 2012 Part 14
Utah and federal law bar false or misleading OTC drug ads, including cure claims, misleading safety or dosage statements and unsupported comparisons.
Utah Code § 58-17b-502(1)(c); 15 U.S.C. § 52; 21 C.F.R. § 201.66(c)
Utah pharmacy marketing must not misrepresent compounded drugs as FDA-approved, mislead on drug prices or efficacy, or offer copay waivers and coupons to federal health program beneficiaries.
15 U.S.C. §§ 45, 52; 42 U.S.C. § 1320a-7a(a)(5); Utah Code § 58-17b-502
OTC drug advertising and labeling for Virginia consumers must stay within approved labeling and avoid false or unsubstantiated efficacy, safety and comparative claims.
15 U.S.C. §§ 45(a), 52(a); 21 U.S.C. § 352(a)(1); Va. Code § 54.1-3462(1)
OTC drug advertising to Vermont consumers must stay within approved labeling and avoid false or unsubstantiated efficacy, safety and comparative claims.
15 U.S.C. § 52; 21 C.F.R. § 201.66; 9 V.S.A. § 2453
Vermont's pharmacy practice law, enforced by the Vermont Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Vermont pharmacy ads.
9 V.S.A. § 2453; 15 U.S.C. § 52; 42 U.S.C. § 1320a-7a
Prescription drug marketing directed to Vermont prescribers is reported to require disclosure of the drug's price and its price relationship to other drugs in the same therapeutic class; the statute needs verification before the rule is enabled.
18 V.S.A. § 4633(a)-(b)
Virginia's pharmacy practice law, enforced by the Virginia Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in Virginia pharmacy ads.
21 U.S.C. §§ 352(a), 353(b)(1), 353a; 42 U.S.C. §§ 1320a-7a(a)(5), 1320a-7b(b); Va. Code § 59.1-200(A)
Washington and federal law bar false or misleading OTC drug ads, including off-label therapeutic claims, unsourced superlatives, misleading Rx comparisons and blanket safety claims.
RCW 69.04.040(5), 69.04.500, 69.04.710, 69.04.720
OTC drug advertising to Wisconsin consumers must stay within approved labeling and avoid false or unsubstantiated efficacy, safety and comparative claims.
FDCA 502 (21 U.S.C. 352); FTC Act 5, 12; Wis. Stat. 100.18
OTC drug advertising to West Virginia consumers must stay within approved labeling and avoid false or unsubstantiated efficacy, safety and comparative claims.
FDCA 502 (21 U.S.C. 352); FTC Act 5, 12; W. Va. Code 46A-6-104
Wyoming and federal law bar false or misleading OTC drug ads, including cure claims, misleading natural or safety claims, implied prescription efficacy and unlimited pediatric claims.
Wyo. Stat. Sec. 40-12-105; Wyo. Stat. Sec. 33-24-101 et seq.; 21 CFR Part 330; FTC Act Secs. 5, 12, 15
Washington pharmacy marketing must not misrepresent compounded drugs as FDA-approved, mislead on drug prices or efficacy, or offer copay waivers and coupons to federal health program beneficiaries.
RCW 18.64; WAC 246-945; RCW 19.86.020; 42 U.S.C. Secs. 1320a-7b(b), 1320a-7a(a)(5)
West Virginia's pharmacy practice law, enforced by the West Virginia Board of Pharmacy, bars false or misleading pharmacy advertising; the rule checks visible compounding, prescription-access, incentive, price and efficacy claims. No license-number or pharmacy-type statement is required in West Virginia pharmacy ads.
W. Va. Code ch. 30, art. 5
Wisconsin pharmacy marketing must not misrepresent compounded drugs as FDA-approved, mislead on drug prices, efficacy or ownership, or offer copay waivers and coupons to federal health program beneficiaries.
Wis. Stat. ch. 450; Wis. Admin. Code ch. Phar; Wis. Stat. Sec. 100.18; 42 U.S.C. Secs. 1320a-7b(b), 1320a-7a(a)(5)
Browse by regulator
- ABA / ABA Formal Op. 480
- ABA / State Bar Associations
- ABA / State Bars
- ACT Government
- AK Department of Revenue
- AK Division of Banking & Securities
- AK State Board of Pharmacy
- AL Department of Revenue
- AL Securities Commission
- AL State Banking Department
- AL State Board of Pharmacy
- AR Department of Health
- AR Motor Vehicle Commission; Arkansas Attorney General
- AR Securities Department
- AR State Board of Pharmacy
- ASIC / Insurance Council of Australia Code Governance Committee
- AZ Corporation Commission — Securities Division
- AZ Department of Health Services
- AZ Department of Insurance and Financial Institutions
- AZ State Board of Pharmacy
- Accessibility Directorate of Ontario
- Advertising Standards Authority (ASA) and Ofcom
- Advertising Standards Canada (ASC)
- Agence Nationale de Securite du Medicament et des Produits de Sante
- Agenzia Italiana del Farmaco
- Alabama AL DOI
- Alabama Attorney General
- Alabama Attorney General / Alabama Department of Revenue Motor Vehicle Division
- Alabama Credit Union Administration
- Alabama Department of Insurance
- Alabama Medical Cannabis Commission (AMCC)
- Alabama Real Estate Commission (AREC)
- Alabama State Banking Department
- Alabama State Bar
- Alabama State Bar / Courts
- Alabama Superintendent of Financial Institutions
- Alaska AK Div Ins
- Alaska Attorney General
- Alaska Attorney General / Alaska Division of Motor Vehicles
- Alaska Bar Association
- Alaska Board of Pharmacy
- Alaska Department of Law
- Alaska Department of Law Criminal Division
- Alaska Department of Revenue
- Alaska Department of Transportation & Public Facilities
- Alaska Division of Banking & Securities
- Alaska Division of Banking and Securities
- Alaska Division of Insurance
- Alaska Marijuana Control Board (MCB)
- Alaska Real Estate Commission
- Alberta Insurance Council (AIC)
- Alberta Securities Commission (ASC)
- Alberta regulated health professional colleges (Health Professions Act)
- Alcohol and Marijuana Control Office (AMCO) / Alcoholic Beverage Control Board
- Alcohol and Tobacco Tax and Trade Bureau (TTB)
- Alcoholic Beverage and Cannabis Administration (ABCA), formerly ABRA
- American Bar Association
- American Bar Association (ABA)
- American Samoa Economic Development Authority (ASDLA)
- American Veterinary Medical Association (AVMA)
- Anti-Money Laundering Authority (AMLA)
- Arizona AZ DIFI
- Arizona Attorney General
- Arizona Attorney General; AZ Department of Transportation MVD
- Arizona Corporation Commission-Securities Division
- Arizona Department of Gaming
- Arizona Department of Health Services (DHS)
- Arizona Department of Insurance and Financial Institutions
- Arizona Department of Insurance and Financial Institutions (DIFI)
- Arizona Department of Real Estate (ADRE)
- Arizona State Board of Pharmacy
- Arkansas AR Ins Dept
- Arkansas Alcoholic Beverage Control Division (ABC), Department of Finance and Administration
- Arkansas Attorney General
- Arkansas Attorney General / prosecuting attorneys
- Arkansas Bar Association
- Arkansas Department of Finance and Administration (ASC)
- Arkansas Insurance Department
- Arkansas Medical Marijuana Commission
- Arkansas Real Estate Commission
- Arkansas State Bank Department / Securities Department
- Arkansas State Bar / Courts
- Arkansas Supreme Court Committee on Professional Conduct
- Asset Management Association Switzerland (AMAS)
- Association of British Insurers (ABI)
- Association of British Insurers (ABI) / UK Financial Conduct Authority (FCA)
- Australia Life Code Compliance Committee (Life CCC)
- Australia NSW Government
- Australian Communications and Media Authority (ACMA)
- Australian Competition and Consumer Commission (ACCC)
- Australian Securities and Investments Commission (ASIC)
- Autorité des marchés financiers (AMF); Office québécois de la langue française (OQLF)
- BBB National Programs — National Advertising Division (NAD) (self-regulatory)
- BC Financial Services Authority (BCFSA)
- BC Financial Services Authority (BCFSA) — Real Estate
- Bank of Canada (under Retail Payments Activities Act)
- Beer Institute
- Board of Governors of the Federal Reserve System
- British Columbia Securities Commission (BCSC)
- British Insurance Brokers' Association (BIBA) / FCA
- Bundesinstitut fur Arzneimittel und Medizinprodukte (BfArM)
- CA Attorney General — Registry of Charities
- CA Board of Pharmacy
- CA Department of Financial Protection and Innovation (DFPI)
- CA Department of Managed Health Care (DMHC) / CA Department of Insurance (CDI)
- CA Department of Motor Vehicles
- CA Department of Public Health
- CO Department of Revenue
- CO Division of Securities
- CO Motor Vehicle Dealer Board; Colorado Attorney General
- CO Office of the Attorney General — Consumer Credit Unit
- CO Secretary of State
- CO State Board of Pharmacy
- CT Department of Banking
- CT Department of Banking — Securities Division
- CT Department of Consumer Protection
- CT Department of Mental Health and Addiction Services
- CT State Department of Consumer Protection - Pharmacy
- California (Health & Safety Code)
- California Attorney General
- California Attorney General / California Office of the Secretary of State
- California Attorney General and local prosecutors
- California Attorney General — Bureau of Consumer Protection
- California CA CDI
- California CA CDI/DMHC
- California Civil Rights Department
- California Department of Alcoholic Beverage Control (ABC)
- California Department of Business Oversight / DFPI
- California Department of Cannabis Control (DCC)
- California Department of Financial Protection & Innovation (DFPI)
- California Department of Financial Protection and Innovation
- California Department of Financial Protection and Innovation (DFPI)
- California Department of Financial Protection and Innovation (DFPI) / NY DFS
- California Department of Food and Agriculture
- California Department of Food and Agriculture (CDFA)
- California Department of Insurance
- California Department of Insurance (CDI)
- California Department of Justice (DOJ)
- California Department of Public Health
- California Department of Real Estate (DRE)
- California Department of Resources Recycling and Recovery (CalRecycle)
- California Gambling Control Commission (CGCC)
- California Horse Racing Board (CHRB)
- California Labor Commissioner (DLSE)
- California Medical Board
- California Office of Environmental Health Hazard Assessment
- California Office of Environmental Health Hazard Assessment (OEHHA)
- California Office of Environmental Health Hazard Assessment (OEHHA) / California Attorney General
- California Privacy Protection Agency (CPPA)
- California Privacy Protection Agency (CPPA) / California Attorney General
- California State Board of Pharmacy
- California courts (private right of action); California Office of Suicide Prevention (reporting)
- Canada Mortgage and Housing Corporation (CMHC)
- Canada Revenue Agency (CRA)
- Canadian Government
- Canadian Human Rights Commission
- Canadian Life and Health Insurance Association (CLHIA)
- Canadian Radio-Television and Telecommunications Commission
- Canadian Securities Administrators (CSA)
- Canadian Securities Administrators (CSA) / Ontario Securities Commission (OSC)
- Canadian Securities Administrators (CSA) — BCSC, ASC, OSC, AMF
- Cannabis Regulators Association (CANNRA) + state cannabis control commissions
- Centers for Medicare & Medicaid Services
- Centers for Medicare & Medicaid Services (CMS)
- Centers for Medicare & Medicaid Services; U.S. Food and Drug Administration (claim accuracy)
- College of Physicians and Surgeons of British Columbia (CPSBC)
- College of Physicians and Surgeons of Manitoba
- Colorado Attorney General
- Colorado CO Div Ins
- Colorado Department of Labor
- Colorado Department of Regulatory Agencies
- Colorado Department of Regulatory Agencies (DORA)
- Colorado Department of Revenue
- Colorado Division of Financial Services
- Colorado Division of Insurance
- Colorado Marijuana Enforcement Division (MED)
- Colorado Office of Attorney Regulation Counsel
- Colorado State Board of Pharmacy
- Commission d'acces a l'information du Quebec (CAI)
- Competition Bureau Canada
- Competition Bureau Canada / provincial insurance regulators
- Conference of State Bank Supervisors (CSBS) — Multi-State
- Connecticut Attorney General
- Connecticut Bar Association
- Connecticut CT DOI
- Connecticut Commission of Pharmacy
- Connecticut Department of Banking
- Connecticut Department of Consumer Protection
- Connecticut Department of Consumer Protection (DCP)
- Connecticut Department of Consumer Protection / CT Department of Motor Vehicles
- Connecticut Department of Labor
- Connecticut Insurance Department
- Consumer Affairs Victoria (CAV)
- Consumer Financial Protection Bureau (CFPB) / FTC
- Consumer Financial Protection Bureau (CFPB) / Interagency
- Consumer Financial Protection Bureau (CFPB); FTC for its institutions
- Consumer Financial Protection Bureau (Regulation I)
- Consumer Product Safety Commission (CPSC)
- Consumer Protection WA (Department of Energy, Mines, Industry Regulation and Safety)
- Consumer Protection, Government of Western Australia
- Corporación Pública para la Supervisión y Seguro de Cooperativas de Puerto Rico (COSSEC)
- Covered California / California Department of Insurance (CDI)
- DC Board of Pharmacy
- DC Department of Health
- DC Department of Insurance, Securities & Banking
- DC Department of Insurance, Securities & Banking (DISB)
- DC Department of Insurance, Securities and Banking
- DC Department of Insurance, Securities and Banking (DISB)
- DC Government / DC Office of the Attorney General
- DE Department of Health
- DE Department of Justice
- DE Office of the Attorney General — Investor Protection
- DE Office of the State Bank Commissioner
- DE State Board of Pharmacy
- DISCUS (Distilled Spirits Council of the United States)
- Delaware Attorney General
- Delaware Attorney General; DE Division of Motor Vehicles
- Delaware DE DOI
- Delaware Department of Insurance
- Delaware Department of Justice (Attorney General)
- Delaware Office of the Marijuana Commissioner (OMC)
- Delaware Office of the State Bank Commissioner
- Delaware Real Estate Commission
- Delaware State Bar Association
- Department of Defense (DoD) / Consumer Financial Protection Bureau (CFPB)
- Department of Justice (DOJ)
- Department of Justice Canada
- Digital Government and Service NL
- District of Columbia Bar
- District of Columbia DC DISB
- Dutch Health and Youth Care Inspectorate
- EU Consumer Protection Cooperation Regulation (EC)
- EU Directorate-General for Financial Stability, Financial Services and Capital Markets Union (FISMA)
- EU national competent authorities (MiFID II); European Securities and Markets Authority (ESMA)
- EU national competent authorities and consumer protection authorities
- Equal Employment Opportunity Commission (EEOC)
- Equality and Human Rights Commission (EHRC)
- European Banking Authority (EBA)
- European Banking Authority (EBA) / ESMA / EIOPA
- European Banking Authority (EBA) / National Competent Authorities
- European Central Bank (ECB)
- European Chemicals Agency (ECHA)
- European Commission (EC)
- European Commission (EC) — Cosmetics
- European Commission (EC) — European AI Office
- European Commission / National Competent Authorities
- European Consumer Protection Cooperation Network (CPC)
- European Data Protection Board (EDPB)
- European Insurance and Occupational Pensions Authority (EIOPA)
- European Medicines Agency (EMA)
- European Securities and Markets Authority (ESMA)
- European Securities and Markets Authority (ESMA) / EU
- European Securities and Markets Authority (ESMA) / European Banking Authority (EBA)
- European Securities and Markets Authority (ESMA) / European Banking Authority (EBA) / National Competent Authorities
- European Supervisory Authorities (ESMA, EBA, EIOPA) and national competent authorities
- FDA Office of Prescription Drug Promotion (OPDP)
- FDIC / OCC / NCUA / HUD
- FL Board of Pharmacy
- FL Department of Agriculture & Consumer Services
- FL Department of Business and Professional Regulation
- FL Department of Highway Safety and Motor Vehicles; Florida Attorney General
- FL Office of Financial Regulation (OFR)
- FL Office of Financial Regulation — Division of Securities
- Federal Communications Commission (FCC)
- Federal Data Protection and Information Commissioner (FDPIC)
- Federal Financial Institutions Examination Council (FFIEC)
- Federal Financial Institutions Examination Council (Interagency Statement) / FINRA
- Federal Housing Finance Agency (FHFA)
- Federal Trade Commission (FTC)
- Federal Trade Commission (FTC) + U.S. Department of Education
- Federal Video Privacy Protection Act / DOJ-FTC
- Federation of State Medical Boards (FSMB) + state medical practice acts (50 states)
- Financial Conduct Authority (UK)
- Financial Consumer Agency of Canada (FCAC)
- Financial Industry Regulatory Authority (FINRA)
- Financial Services Regulatory Authority of Ontario
- Financial Services Regulatory Authority of Ontario (FSRA)
- Financial Transactions and Reports Analysis Centre of Canada
- Financial and Consumer Affairs Authority of Saskatchewan (FCAA)
- Financial and Consumer Services Commission of New Brunswick (FCNB)
- Florida Attorney General
- Florida Board of Medicine
- Florida Board of Pharmacy
- Florida Department of Agriculture & Consumer Services (FDACS)
- Florida Department of Agriculture and Consumer Services (FDACS)
- Florida Department of Financial Services
- Florida Department of Financial Services / Office of Insurance Regulation
- Florida Department of Health
- Florida FL OIR
- Florida Gaming Control Commission (FGCC)
- Florida Office of Attorney General
- Florida Office of Financial Regulation
- Florida Office of Financial Regulation (OFR)
- Florida Office of Insurance Regulation
- Florida Office of Insurance Regulation (OIR)
- Florida Office of Insurance Regulation (OIR) / Florida Department of Financial Services (DFS)
- Florida Real Estate Commission (FREC)
- Florida State Bar / Courts
- Food and Drug Administration — Center for Veterinary Medicine (CVM)
- GA Department of Banking and Finance
- GA Department of Revenue
- GA Office of the Secretary of State — Securities Division
- GA Secretary of State
- GA State Board of Pharmacy
- Gambling Control Board (Minnesota)
- Georgia Attorney General
- Georgia Attorney General (Consumer Protection Division)
- Georgia Attorney General's Consumer Protection Division
- Georgia Board of Pharmacy
- Georgia Bureau of Investigation (GBI)
- Georgia Department of Banking and Finance
- Georgia Department of Banking and Finance (DBF)
- Georgia Department of Law Consumer Protection Division; GA Board of Used Motor Vehicle Dealers
- Georgia GA OCSFC
- Georgia Office of Insurance and Safety Fire Commissioner
- Georgia Real Estate Commission
- Georgia State Bar / Courts
- Gobierno de Puerto Rico Departamento de Asuntos del Consumidor (DACO)
- Gobierno de Puerto Rico La Oficina del Comisionado de Instituciones Financieras (OCIF)
- Google
- Google Ads
- Guam Attorney General
- Guam Banking and Insurance Commissioner (Department of Revenue and Taxation)
- Guam Cannabis Control Board (under Department of Revenue and Taxation)
- Guam Department of Revenue and Taxation
- Guam Department of Revenue and Taxation - Securities
- Guam Insurance Commissioner (Department of Revenue and Taxation)
- Guam Real Estate Commission
- HHS Office for Civil Rights (OCR)
- HHS Office of Inspector General
- HI DCCA Motor Vehicle Industry Licensing Board
- HI Department of Commerce & Consumer Affairs (DCCA)
- HI Department of Commerce & Consumer Affairs — Securities
- HI Department of Health
- HI Department of the Attorney General
- HI State Board of Pharmacy
- HM Revenue & Customs (HMRC)
- Hawaii Attorney General
- Hawaii Board of Pharmacy
- Hawaii Department of Commerce and Consumer Affairs (DCCA)
- Hawaii Department of Health — Medical Cannabis Registry
- Hawaii Department of Taxation; County Tax Collectors
- Hawaii Division of Financial Institutions
- Hawaii HI Ins Div
- Hawaii Insurance Division (DCCA)
- Hawaii Insurance Division (within DCCA)
- Hawaii Office of Consumer Protection (OCP)
- Hawaii Office of Disciplinary Counsel
- Hawaii Real Estate Commission
- Health Canada
- Health Canada - Cannabis Control Division
- IA Board of Pharmacy
- IA Department of Public Health
- IA Division of Banking
- IA Division of Insurance — Securities Bureau
- ID Department of Finance
- ID Department of Finance — Securities
- ID Department of Health and Welfare
- ID State Board of Pharmacy
- IL Attorney General — Charitable Trust Bureau
- IL Attorney Registration and Disciplinary Commission
- IL Department of Financial and Professional Regulation
- IL Department of Public Health
- IL Secretary of State — Securities Department
- IL State Board of Pharmacy
- IN Department of Financial Institutions
- IN Excise Police
- IN Secretary of State Auto Dealer Services Division; Indiana Attorney General
- IN Secretary of State — Securities Division
- IN State Board of Pharmacy
- Idaho Attorney General
- Idaho Attorney General / Idaho Lottery Commission
- Idaho Attorney General; ID Transportation Department / Division of Motor Vehicles
- Idaho Board of Pharmacy
- Idaho Department of Finance
- Idaho Department of Insurance
- Idaho ID DOI
- Idaho Real Estate Commission
- Idaho State Bar
- Idaho State Liquor Division (ISLD)
- Illinois ARDC
- Illinois Attorney General
- Illinois Attorney General — Consumer Fraud Bureau
- Illinois Attorney General; IL Secretary of State Vehicle Services Department
- Illinois Attorney Registration and Disciplinary Commission
- Illinois Commerce Commission
- Illinois Department of Financial and Professional Regulation
- Illinois Department of Financial and Professional Regulation (IDFPR)
- Illinois Department of Financial and Professional Regulation (IDFPR) + Department of Agriculture (cultivation)
- Illinois Department of Financial and Professional Regulation — Pharmacy
- Illinois Department of Human Rights
- Illinois Department of Insurance
- Illinois Department of Insurance (within DFPR)
- Illinois Department of Labor
- Illinois Department of Labor / Illinois Attorney General
- Illinois Gaming Board (IGB)
- Illinois IL DOI
- Illinois Liquor Control Commission
- Indiana Attorney General
- Indiana Department of Financial Institutions
- Indiana Department of Insurance
- Indiana Gaming Commission
- Indiana IN DOI
- Indiana Office of the Attorney General
- Indiana Real Estate Commission (IREC)
- Indiana State Board of Pharmacy
- Indiana Supreme Court Disciplinary Commission
- Industry Best Practices (Cross-Regulator)
- Information and Privacy Commissioner of Ontario
- Insurance Code Governance Committee (CGC); Australian Securities and Investments Commission (ASIC)
- Insurance Council of Manitoba
- Internal Revenue Service (IRS)
- Iowa Alcoholic Beverages Division (ABD)
- Iowa Attorney General
- Iowa Attorney General; IA Department of Transportation MVD
- Iowa Board of Pharmacy
- Iowa Department of Health and Human Services (HHS) — Office of Medical Cannabidiol
- Iowa Division of Banking (IDOB)
- Iowa Division of Credit Unions
- Iowa IA Ins Div
- Iowa Insurance Division
- Iowa Racing and Gaming Commission
- Iowa Real Estate Commission
- Iowa Supreme Court Attorney Disciplinary Board
- KS Department of Revenue
- KS Office of the Securities Commissioner
- KS Office of the State Bank Commissioner
- KS Secretary of State
- KS State Board of Pharmacy
- KY Attorney General
- KY Board of Pharmacy
- KY Department of Alcoholic Beverage Control
- KY Department of Financial Institutions
- KY Department of Financial Institutions — Securities
- KY Motor Vehicle Commission
- Kansas Alcoholic Beverage Control (ABC)
- Kansas Attorney General
- Kansas Attorney General; KS Department of Revenue / Vehicle Dealers
- Kansas Department of Credit Unions
- Kansas Department of Insurance
- Kansas Insurance Department
- Kansas KS Ins Dept
- Kansas Office of the Disciplinary Administrator
- Kansas Office of the State Bank Commissioner
- Kansas Racing and Gaming Commission
- Kansas Real Estate Commission
- Kansas State Board of Pharmacy
- Kentucky Alcoholic Beverage Control (ABC)
- Kentucky Attorney General
- Kentucky Bar Association
- Kentucky Board of Medical Licensure
- Kentucky Board of Pharmacy
- Kentucky Cabinet for Health and Family Services — Office of Medical Cannabis
- Kentucky Department of Financial Institutions
- Kentucky Department of Insurance
- Kentucky Horse Racing and Gaming Corporation (KHRGC)
- Kentucky KY DOI
- Kentucky Office of the Attorney General
- Kentucky Real Estate Commission
- LA Board of Pharmacy
- LA Department of Health
- LA Department of Justice
- LA Motor Vehicle Commission
- LA Office of Financial Institutions
- LA Office of Financial Institutions — Securities
- Lanham Act (private right of action)
- Lanham Act (private right of action; federal courts)
- LinkedIn
- LinkedIn Marketing Solutions
- Lloyd's of London (Corporation) / Lloyd's Market Association (LMA)
- Louisiana Attorney General
- Louisiana Board of Pharmacy
- Louisiana Department of Health — Medical Marijuana Program
- Louisiana Department of Insurance
- Louisiana Department of Justice (Attorney General)
- Louisiana Gaming Control Board (LGCB)
- Louisiana LA DOI
- Louisiana Office of Alcohol and Tobacco Control (ATC)
- Louisiana Office of Financial Institutions
- Louisiana Office of Financial Institutions (OFI)
- Louisiana Real Estate Commission (LREC)
- Louisiana State Bar / Courts
- Louisiana State Bar Association
- MA Attorney General — Non-Profit Organizations / Public Charities Division
- MA Board of Pharmacy
- MA Department of Revenue
- MA Division of Banks
- MA Securities Division — Office of the Secretary
- MD Department of Health
- MD Motor Vehicle Administration
- MD Office of the Commissioner of Financial Regulation
- MD Secretary of State
- MD Securities Division — Office of the Attorney General
- MD State Board of Pharmacy
- ME Board of Pharmacy
- ME Bureau of Consumer Credit Protection
- ME Department of Health and Human Services
- ME Office of Professional and Occupational Regulation
- ME Office of Securities
- MI Department of Insurance and Financial Services (DIFS)
- MI Department of Licensing and Regulatory Affairs — Securities
- MI Department of State; Michigan Attorney General
- MI Department of Treasury
- MI Department of the Attorney General
- MN Attorney General
- MN Board of Pharmacy
- MN Department of Agriculture
- MN Department of Commerce
- MN Department of Commerce — Securities
- MN Department of Public Safety Driver and Vehicle Services; Minnesota Attorney General
- MN Department of Revenue
- MO Attorney General
- MO Board of Pharmacy
- MO Department of Public Safety
- MO Department of Revenue; Missouri Attorney General
- MO Division of Finance
- MO Secretary of State — Securities Division
- MS Department of Banking and Consumer Finance
- MS Department of Revenue
- MS Motor Vehicle Commission
- MS Secretary of State
- MS Secretary of State — Business Regulation
- MS State Board of Pharmacy
- MT Board of Pharmacy
- MT Commissioner of Securities and Insurance
- MT Department of Justice Motor Vehicle Division
- MT Division of Banking and Financial Institutions
- Maine Attorney General
- Maine Attorney General (10 M.R.S. 1499-G); Maine Bureau of Insurance (24-A M.R.S. 2152-C)
- Maine Attorney General / Maine Bureau of Motor Vehicles
- Maine Board of Overseers of the Bar
- Maine Board of Pharmacy
- Maine Bureau of Alcoholic Beverages and Lottery Operations (BABLO)
- Maine Bureau of Consumer Credit Protection
- Maine Bureau of Financial Institutions
- Maine Bureau of Insurance
- Maine Department of Environmental Protection
- Maine Gambling Control Board
- Maine Gambling Control Unit (Department of Public Safety)
- Maine ME BOI
- Maine Office of Cannabis Policy (OCP)
- Manitoba Accessibility Office
- Manitoba Government
- Manitoba Securities Commission (MSC); Consumer Protection Office Manitoba
- Manitoba Securities Commission (Manitoba Financial Services Agency)
- Maryland Alcohol, Tobacco, and Cannabis Commission (ATCC)
- Maryland Attorney General
- Maryland Attorney General (Consumer Protection Division)
- Maryland Board of Pharmacy
- Maryland Cannabis Administration (MCA)
- Maryland Commissioner of Financial Regulation
- Maryland Department of Labor
- Maryland Department of Labor Office of Financial Regulation
- Maryland Insurance Administration
- Maryland MD MIA
- Maryland Office of Financial Regulation
- Maryland Real Estate Commission
- Maryland State Lottery & Gaming Control Agency
- Mass. Board of Bar Overseers
- Massachusetts Attorney General
- Massachusetts Attorney General — Consumer Protection Division
- Massachusetts Board of Bar Overseers
- Massachusetts Board of Registration in Pharmacy
- Massachusetts Cannabis Control Commission (CCC)
- Massachusetts Department of Environmental Protection
- Massachusetts Division of Banks
- Massachusetts Division of Banks (DOB)
- Massachusetts Division of Insurance
- Massachusetts Division of Insurance / Health Connector Authority
- Massachusetts Gaming Commission
- Massachusetts MA DOI
- Medicines and Healthcare products Regulatory Agency (MHRA)
- Meta (Instagram, Facebook)
- Meta Platforms
- Michigan Attorney General
- Michigan Board of Pharmacy
- Michigan Cannabis Regulatory Agency (CRA, formerly MRA)
- Michigan Department of Environment, Great Lakes, and Energy
- Michigan Department of Insurance and Financial Services
- Michigan Department of Insurance and Financial Services (DIFS)
- Michigan Department of Labor and Economic Opportunity
- Michigan Gaming Control Board
- Michigan Licensing and Regulatory Affairs
- Michigan MI DIFS
- Microsoft Advertising (Bing Ads)
- Minnesota Attorney General
- Minnesota Board of Pharmacy
- Minnesota Department of Commerce
- Minnesota Department of Labor and Industry
- Minnesota MN Dept Commerce
- Minnesota MN Dept of Commerce
- Minnesota Office of Cannabis Management (OCM)
- Minnesota Office of Lawyers Professional Responsibility
- Minnesota Pollution Control Agency
- Mississippi Attorney General
- Mississippi Bar
- Mississippi Board of Pharmacy
- Mississippi Department of Banking and Consumer Finance
- Mississippi Department of Banking and Consumer Finance (DBCF)
- Mississippi Gaming Commission
- Mississippi Gaming Commission (MGC)
- Mississippi Insurance Department
- Mississippi MS Ins Dept
- Mississippi Real Estate Commission
- Missouri Attorney General
- Missouri Bar / Supreme Court of Missouri
- Missouri Department of Cannabis Regulation (DCR, within Department of Health and Senior Services)
- Missouri Department of Commerce and Insurance
- Missouri Department of Commerce and Insurance (DCI)
- Missouri Division of Alcohol & Tobacco Control
- Missouri Division of Credit Unions
- Missouri Division of Finance
- Missouri Gaming Commission
- Missouri Lottery Commission
- Missouri MO Dept Commerce/Ins
- Missouri Real Estate Commission
- Missouri State Board of Pharmacy
- Montana Attorney General
- Montana Board of Pharmacy
- Montana Board of Realty Regulation
- Montana Commissioner of Securities and Insurance
- Montana Commissioner of Securities and Insurance (CSI)
- Montana Department of Justice, Gambling Control Division
- Montana Department of Revenue — Cannabis Control Division (CCD)
- Montana Division of Banking & Financial Institutions
- Montana Division of Banking and Financial Institutions
- Montana Gambling Control Division
- Montana MT CSI
- Municipal Securities Rulemaking Board (MSRB)
- NC Board of Pharmacy
- NC Department of Revenue
- NC Department of the Secretary of State — Securities Division
- NC Division of Motor Vehicles; North Carolina Attorney General
- NC Office of the Commissioner of Banks
- NC Secretary of State
- ND DOT Motor Vehicle Division; North Dakota Attorney General
- ND Department of Financial Institutions
- ND Department of Health
- ND Secretary of State
- ND Securities Commissioner
- ND State Board of Pharmacy
- NE Department of Banking and Finance
- NE Department of Banking and Finance — Bureau of Securities
- NE Department of Health - Pharmacy
- NE Motor Vehicle Industry Licensing Board
- NH Banking Department
- NH Board of Pharmacy
- NH Bureau of Securities Regulation
- NH Department of Justice
- NH Department of Safety Division of Motor Vehicles; New Hampshire Attorney General
- NJ Bureau of Securities
- NJ Department of Banking and Insurance
- NJ Division of Consumer Affairs
- NJ State Board of Pharmacy
- NM Board of Pharmacy
- NM Department of Health
- NM Financial Institutions Division
- NM Motor Vehicle Division; New Mexico Attorney General
- NM Securities Division
- NT Agents Licensing Board / NT Consumer Affairs
- NV Department of Motor Vehicles
- NV Financial Institutions Division
- NV Secretary of State — Securities Division
- NV State Board of Pharmacy
- NY Attorney General — Charities Bureau
- NY Department of Environmental Conservation
- NY Department of Financial Services
- NY Department of Law — Investor Protection Bureau
- NY Department of Motor Vehicles / New York Attorney General
- NY State Bar / Courts
- NY State Bar Association
- NY State Bar Association / NY Courts
- NY State Board of Pharmacy
- NY State Department of Health
- NYC Department of Health and Mental Hygiene
- NYC Mayor's Office of Special Enforcement (OSE)
- National Advertising Division (NAD)
- National Advertising Review Board (NARB)
- National Association of Insurance Commissioners (NAIC) / State Insurance Departments
- National Association of REALTORS (NAR)
- National Highway Traffic Safety Administration (NHTSA)
- National Oceanic and Atmospheric Administration
- Nationwide Multistate Licensing System (NMLS) — administered by Conference of State Bank Supervisors (CSBS)
- Nebraska Attorney General
- Nebraska Board of Pharmacy
- Nebraska Department of Banking and Finance
- Nebraska Department of Insurance
- Nebraska Department of Revenue
- Nebraska NE DOI
- Nebraska Real Estate Commission
- Nebraska State Bar Association
- Nevada Attorney General
- Nevada Cannabis Compliance Board (CCB)
- Nevada Department of Labor
- Nevada Division of Financial Institutions
- Nevada Division of Insurance
- Nevada Division of Mortgage Lending
- Nevada Financial Institutions Division (FID)
- Nevada Gaming Commission Gaming Control Board
- Nevada Gaming Control Board (for casino properties); Nevada Attorney General
- Nevada NV Div Ins
- Nevada State Bar / Courts
- Nevada State Board of Pharmacy
- New Hampshire Attorney General
- New Hampshire Banking Department
- New Hampshire Bar Association
- New Hampshire Board of Pharmacy
- New Hampshire Department of Health and Human Services — Therapeutic Cannabis Program
- New Hampshire Insurance Department
- New Hampshire NH DOI
- New Hampshire Real Estate Commission
- New Hampshire State Banking Department
- New Jersey Attorney General
- New Jersey Attorney General (Division of Consumer Affairs)
- New Jersey Attorney General / Division of Consumer Affairs
- New Jersey Board of Pharmacy
- New Jersey Cannabis Regulatory Commission (CRC)
- New Jersey Department of Banking and Insurance
- New Jersey Department of Banking and Insurance (DOBI)
- New Jersey Department of Environmental Protection (NJDEP)
- New Jersey Division of Alcoholic Beverage Control (ABC)
- New Jersey Division of Consumer Affairs
- New Jersey Division of Gaming Enforcement (DGE)
- New Jersey NJ DOBI
- New Jersey Real Estate Commission (NJDOBI)
- New Mexico Alcohol & Gaming Division
- New Mexico Attorney General
- New Mexico Board of Pharmacy
- New Mexico Cannabis Control Division (CCD)
- New Mexico Financial Institutions Division
- New Mexico Gaming Control Board
- New Mexico NM OSI
- New Mexico Office of Superintendent of Insurance
- New Mexico Office of the Superintendent of Insurance (OSI)
- New Mexico Real Estate Commission
- New Mexico Regulation and Licensing Department
- New York Attorney General
- New York Attorney General + NYSERDA
- New York Attorney General — Office of Investor Protection
- New York City Department of Consumer and Worker Protection (DCWP)
- New York Department of Environmental Conservation
- New York Department of Financial Services (DFS)
- New York Department of Financial Services (NYDFS)
- New York Department of State's Division of Licensing Services (DLS)
- New York NY DFS
- New York Office of Cannabis Management (OCM)
- New York Public Service Commission
- New York State Attorney General
- New York State Board of Pharmacy
- New York State Department of Environmental Conservation
- New York State Department of Financial Services
- New York State Department of Labor
- New York State Gaming Commission
- New York State Liquor Authority (SLA)
- New York courts (private right of action by rights holders)
- North American Securities Administrators Association (NASAA)
- North Carolina ABC Commission
- North Carolina Attorney General
- North Carolina Board of Pharmacy
- North Carolina Commissioner of Banks
- North Carolina Credit Union Division
- North Carolina Department of Agriculture and Consumer Services
- North Carolina Department of Insurance
- North Carolina Medical Board
- North Carolina NC DOI
- North Carolina Office of the Commissioner of Banks (NCCOB)
- North Carolina Real Estate Commission
- North Carolina State Bar
- North Carolina State Lottery Commission (NCSLC)
- North Dakota Attorney General
- North Dakota Department of Financial Institutions
- North Dakota Department of Health and Human Services — Medical Marijuana Division
- North Dakota Insurance Department
- North Dakota ND Ins Dept
- North Dakota ND Workforce Safety & Insurance
- North Dakota Office of State Tax Commissioner — Alcohol Tax
- North Dakota Real Estate Commission
- North Dakota State Board of Pharmacy
- Northern Territory Agents Licensing Board
- Nova Scotia Real Estate Commission (NSREC)
- Nova Scotia Securities Commission (NSSC); Service Nova Scotia (consumer affairs)
- OH Attorney General — Charitable Law Section
- OH Department of Commerce — Division of Financial Institutions
- OH Department of Commerce — Division of Securities
- OH Department of Health
- OH State Board of Pharmacy
- OK Department of Consumer Credit
- OK Department of Securities
- OK Motor Vehicle Commission
- OK Secretary of State
- OK State Board of Pharmacy
- OK Tax Commission
- OR Department of Justice
- OR Division of Financial Regulation
- OR Division of Financial Regulation — Securities
- OR Health Authority
- OR State Board of Pharmacy
- Office de la protection du consommateur (OPC)
- Office des professions du Quebec (OPQ)
- Office for Civil Rights, Department of Health and Human Services (HHS OCR)
- Office of Inspector General (OIG)
- Office of the Australian Information Commissioner (OAIC)
- Office of the Information and Privacy Commissioner of Alberta (OIPC)
- Office of the Information and Privacy Commissioner of British Columbia
- Office of the Privacy Commissioner of Canada
- Office of the Superintendent of Financial Institutions (OSFI)
- Office of the Superintendent of Financial Institutions (OSFI) / Financial Consumer Agency of Canada (FCAC)
- Office of the Superintendent of Insurance (NL)
- Office of the Superintendent of Insurance (Nova Scotia)
- Office of the Superintendent of Insurance (PEI)
- Office of the Superintendent of Securities (NWT)
- Office of the Superintendent of Securities (Newfoundland and Labrador); Digital Government and Service NL - Consumer Affairs
- Office of the Superintendent of Securities (Nunavut)
- Office of the Superintendent of Securities (PEI); PEI Consumer Affairs
- Ohio Attorney General
- Ohio Casino Control Commission
- Ohio Department of Agriculture
- Ohio Department of Commerce
- Ohio Department of Commerce — Division of Cannabis Control (DCC)
- Ohio Department of Commerce — Division of Liquor Control
- Ohio Department of Commerce, Division of Financial Institutions
- Ohio Department of Insurance
- Ohio Disciplinary Counsel
- Ohio Division of Financial Institutions
- Ohio OH Bureau of Workers' Comp
- Ohio OH DOI
- Ohio State Board of Pharmacy
- Ohio State Medical Board
- Ohio Supreme Court Disciplinary Counsel
- Oklahoma Alcoholic Beverage Laws Enforcement Commission (ABLE)
- Oklahoma Attorney General
- Oklahoma Banking Department
- Oklahoma Bar Association
- Oklahoma Department of Consumer Credit
- Oklahoma Insurance Department
- Oklahoma Medical Marijuana Authority (OMMA)
- Oklahoma OK Ins Dept
- Oklahoma Office of Attorney General
- Oklahoma Real Estate Commission
- Oklahoma State Banking Department
- Oklahoma State Board of Pharmacy
- Ontario Health Regulatory Colleges
- Ontario Ministry of Labour
- Ontario Securities Commission (OSC)
- Oregon Attorney General / Oregon DMV
- Oregon Department of Consumer and Business Services (DCBS)
- Oregon Department of Environmental Quality (DEQ)
- Oregon Department of Justice
- Oregon Division of Financial Regulation
- Oregon Division of Financial Regulation (DFR)
- Oregon Liquor and Cannabis Commission (OLCC)
- Oregon OR DFR
- Oregon Real Estate Agency
- Oregon State Bar
- Oregon State Board of Pharmacy
- Oregon State Lottery Commission
- Organisme d'autoréglementation du courtage immobilier du Québec (OACIQ)
- PA Department of Banking and Securities
- PA Department of Banking and Securities — Bureau of Securities
- PA Department of Revenue
- PA Department of State — Bureau of Corporations and Charitable Organizations
- PA Gaming Control Board
- PA State Board of Pharmacy
- PEI Department of Justice and Public Safety — Consumer Affairs / Real Estate
- PR Department of Consumer Affairs
- Payment Card Networks (Visa, Mastercard)
- Pennsylvania Attorney General
- Pennsylvania Attorney General; PA State Board of Vehicle Manufacturers, Dealers and Salespersons
- Pennsylvania Bar Association / Disciplinary Board
- Pennsylvania Department of Banking and Securities
- Pennsylvania Department of Banking and Securities (DoBS)
- Pennsylvania Department of Health — Office of Medical Marijuana
- Pennsylvania Disciplinary Board
- Pennsylvania Gaming Control Board
- Pennsylvania Insurance Department
- Pennsylvania Liquor Control Board
- Pennsylvania Liquor Control Board (PLCB)
- Pennsylvania PA Ins Dept
- Pennsylvania Public Utility Commission
- Pennsylvania Real Estate Commission
- Pennsylvania State Board of Medicine
- Pennsylvania State Board of Pharmacy
- Private enforcement (competitors in federal court)
- Provincial Consumer Protection Regulators (Consumer Protection BC, Alberta SCO, Ontario MGCS, etc.)
- Provincial insurance regulators (CCIR/CISRO members)
- Public Utility Commission of Texas (PUCT)
- Puerto Rico Departamento de Estado
- Puerto Rico Department of Health — Medical Cannabis Regulatory Board
- Puerto Rico Gaming Commission (CJPR)
- Puerto Rico La Oficina del Comisionado de Instituciones Financieras (OCIF)
- Puerto Rico Office of the Commissioner of Insurance (OCS)
- Puerto Rico Public Corporation for the Supervision and Insurance of Cooperatives (COSSEC)
- Puerto Rico Tourism Company
- Quebec: Autorite des marches financiers
- Quebec: Office de la protection du consommateur
- Quebec: Office quebecois de la langue francaise
- Queensland: Office of Fair Trading (OFT)
- RI Board of Pharmacy
- RI Department of Business Regulation
- RI Department of Business Regulation — Securities Division
- RI Department of Health
- RI Department of Revenue / Division of Motor Vehicles
- Real Estate Council of Alberta (RECA)
- Real Estate Council of Ontario (RECO)
- Rhode Island Attorney General
- Rhode Island Bar Association
- Rhode Island Board of Pharmacy
- Rhode Island Cannabis Control Commission (CCC)
- Rhode Island Department of Business Regulation
- Rhode Island Department of Business Regulation - Insurance Division
- Rhode Island Department of Business Regulation — Insurance Division
- Rhode Island Department of Business Regulation — Liquor Enforcement
- Rhode Island Office of the Attorney General
- Rhode Island RI DBR
- Rhode Island State Police
- SC Board of Pharmacy
- SC Department of Motor Vehicles (licensing) / SC Department of Consumer Affairs (closing fee)
- SC Department of Revenue
- SC Office of the Attorney General — Securities Division
- SC Secretary of State
- SC State Board of Financial Institutions (Consumer Finance Division); SC Department of Consumer Affairs
- SD Department of Revenue
- SD Department of Revenue Motor Vehicle Division
- SD Division of Banking
- SD Division of Insurance — Securities Regulation
- SD State Board of Pharmacy
- Saskatchewan Real Estate Commission (SREC)
- South Australia Consumer & Business Services
- South Carolina Attorney General
- South Carolina Bar / SC Office of Disciplinary Counsel
- South Carolina Board of Financial Institutions
- South Carolina Board of Pharmacy
- South Carolina Consumer Finance Division
- South Carolina Department of Consumer Affairs
- South Carolina Department of Insurance
- South Carolina Department of Insurance (SCDOI)
- South Carolina Department of Revenue — ABC
- South Carolina Law Enforcement Division
- South Carolina Real Estate Commission
- South Carolina Real Estate Commission (LLR)
- South Carolina SC DOI
- South Dakota Attorney General
- South Dakota Board of Pharmacy
- South Dakota Department of Health — Medical Cannabis Program
- South Dakota Department of Revenue
- South Dakota Division of Banking
- South Dakota Division of Insurance
- South Dakota Real Estate Commission
- South Dakota SD Div Ins
- Standard Advertising Policies (Cross-Regulator)
- State Attorneys General (Charitable Solicitation)
- State Banking/Financial Services Regulators — VA Bureau of Financial Institutions, FL OFR, NV DBI, CA DFPI
- State Bar Association of North Dakota
- State Bar of Arizona
- State Bar of California
- State Bar of Georgia
- State Bar of Michigan
- State Bar of Montana
- State Bar of Nevada
- State Bar of New Mexico
- State Bar of South Dakota
- State Bar of Texas
- State Bar of Wisconsin
- State Environmental Agencies / Departments of Revenue
- State Insurance Authority of the insurer's domicile under GLBA Title V
- State Insurance Commissioners and Pharmacy Boards
- State Insurance Departments + FTC
- State Secretariat for Economic Affairs (SECO)
- State charity regulators (OH, LA, CA AG) / FTC
- State insurance regulators (Liability Risk Retention Act)
- State insurance regulators (Liability Risk Retention Act; NAIC Model 880 as enacted)
- Supreme Court of Maryland
- Supreme Court of Maryland (Attorney Grievance Commission)
- Supreme Court of New Jersey
- Supreme Court of New Jersey / NJ State Bar
- Swiss Civil Courts
- Swiss Financial Market Supervisory Authority (FINMA)
- Swiss Institute of Intellectual Property (IPI)
- Swiss State Secretariat for Economic Affairs (SECO); Swiss Federal Office of Communications (OFCOM/BAKOM)
- Swiss civil courts (no regulator)
- Swissmedic
- TN Board of Professional Responsibility
- TN Department of Commerce and Insurance — Securities Division
- TN Department of Financial Institutions
- TN Department of Revenue
- TN Motor Vehicle Commission
- TN Secretary of State
- TN State Board of Pharmacy
- TX Comptroller
- TX Department of Motor Vehicles
- TX Department of State Health Services
- TX Office of Consumer Credit Commissioner (OCCC)
- TX State Board of Pharmacy
- TX State Securities Board
- Tasmania: Consumer Building and Occupational Services (CBOS)
- Tennessee Alcoholic Beverage Commission
- Tennessee Alcoholic Beverage Commission (TABC)
- Tennessee Attorney General
- Tennessee Board of Pharmacy
- Tennessee Commerce & Insurance (TDCI)
- Tennessee Department of Commerce and Insurance
- Tennessee Department of Commerce and Insurance — Insurance Division
- Tennessee Department of Financial Institutions
- Tennessee Department of Financial Institutions (TDFI)
- Tennessee Real Estate Commission
- Tennessee Sports Wagering Council
- Tennessee TN DCI
- Texas Alcoholic Beverage Commission (TABC)
- Texas Attorney General
- Texas Attorney General / Texas Department of Information Resources
- Texas Attorney General — Consumer Protection Division
- Texas Credit Union Department
- Texas Department of Banking
- Texas Department of Insurance
- Texas Department of Insurance (TDI)
- Texas Department of Public Safety (DPS) — Compassionate Use Program
- Texas Department of Savings and Mortgage Lending (SML)
- Texas Department of State Health Services
- Texas Lottery Commission
- Texas Medical Board
- Texas Office of Consumer Credit Commissioner (OCCC)
- Texas Real Estate Commission (TREC)
- Texas State Bar / Courts
- Texas State Board of Pharmacy
- Texas TX TDI
- The Florida Bar
- TikTok
- U.K. Civil - Courts and Tribunals Judiciary
- U.K. General Medical Council (GMC)
- U.K. Government Digital Service (GDS)
- U.K. Information Commissioner's Office (ICO)
- U.K. Medicines and Healthcare products Regulatory Agency (MHRA)
- U.K. National Health Service (NHS)
- U.K. National Trading Standards Estate and Letting Agency Teams (NTSELAT)
- U.K. Royal Institution of Chartered Surveyors (RICS)
- U.S. Commodity Futures Trading Commission (CFTC)
- U.S. Commonwealth of the Northern Mariana Islands (CNMI)
- U.S. Consumer Financial Protection Bureau (CFPB)
- U.S. Consumer Financial Protection Bureau (CFPB) / FDIC / OCC / NCUA
- U.S. Consumer Financial Protection Bureau (CFPB) / U.S. Federal Trade Commission (FTC)
- U.S. Consumer Financial Protection Bureau (CFPB) under FCRA Section 624
- U.S. Consumer Product Safety Commission (CPSC)
- U.S. Customs and Border Protection
- U.S. Customs and Border Protection (CBP)
- U.S. Department of Agriculture (USDA) — Agricultural Marketing Service
- U.S. Department of Defense
- U.S. Department of Education
- U.S. Department of Energy
- U.S. Department of Health and Human Services (HHS); IRS; Department of Labor
- U.S. Department of Health and Human Services Office of Inspector General (OIG)
- U.S. Department of Housing and Urban Development (HUD)
- U.S. Department of Justice (DOJ)
- U.S. Department of Justice (DOJ); state attorneys general and gaming regulators
- U.S. Department of Justice under ADA Title III
- U.S. Department of Labor (DOL)
- U.S. Department of Labor (DOL); HHS; IRS
- U.S. Department of Transportation (DOT)
- U.S. Department of Veterans Affairs (VA) / U.S. Department of Education (ED)
- U.S. Department of the Treasury
- U.S. Department of the Treasury / Federal and state payment stablecoin regulators
- U.S. Departments of HHS, Labor and Treasury; Centers for Medicare & Medicaid Services; U.S. Food and Drug Administration (claim accuracy)
- U.S. Drug Enforcement Administration (DEA)
- U.S. Drug Enforcement Administration (DOJ)
- U.S. Environmental Protection Agency
- U.S. Federal Communications Commission (FCC)
- U.S. Federal Communications Commission (FCC) / Federal Election Commission (FEC)
- U.S. Federal Courts (FRCP Rule 23 — Class Actions)
- U.S. Federal Courts (PSLRA — 15 U.S.C. 78u-4)
- U.S. Federal Deposit Insurance Corporation (FDIC)
- U.S. Federal Reserve / OCC / FDIC
- U.S. Federal Reserve Board (FRB)
- U.S. Federal Reserve Board / FDIC / OCC (Interagency)
- U.S. Federal Trade Commission (FTC)
- U.S. Federal Trade Commission (FTC) + AAFCO
- U.S. Federal Trade Commission (FTC) + Internal Revenue Service (IRS)
- U.S. Federal Trade Commission (FTC) + State Attorneys General
- U.S. Federal Trade Commission (FTC) / U.S. Consumer Product Safety Commission (CPSC)
- U.S. Federal Trade Commission (FTC) and State Attorneys General
- U.S. Federal Trade Commission (FTC) and U.S. Federal Communications Commission (FCC)
- U.S. Federal Trade Commission (FTC); U.S. Consumer Financial Protection Bureau (CFPB)
- U.S. Financial Crimes Enforcement Network (FinCEN)
- U.S. Food and Drug Administration (FDA)
- U.S. Food and Drug Administration (FDA) + state cottage food laws (varies — e.g., Cal. Health & Safety Code § 113758; Tex. Health & Safety Code § 437.001; Fla. Stat. § 500.80)
- U.S. Food and Drug Administration (FDA); Florida Department of Business and Professional Regulation (DBPR)
- U.S. Food and Drug Administration (FDA); USDA
- U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch)
- U.S. Internal Revenue Service (IRS)
- U.S. National Association of Insurance Commissioners (NAIC)
- U.S. National Association of Insurance Commissioners (NAIC) and adopting State Insurance Departments
- U.S. National Association of Realtors (NAR)
- U.S. National Credit Union Administration (NCUA)
- U.S. Nationwide Mortgage Licensing System & Registry (NMLS)
- U.S. Office of Foreign Assets Control
- U.S. Office of Foreign Assets Control (OFAC)
- U.S. Office of the Comptroller of the Currency (OCC)
- U.S. Postal Service (USPS)
- U.S. Postal Service / Federal Express / United Parcel Service
- U.S. Securities and Exchange Commission
- U.S. Securities and Exchange Commission (SEC)
- U.S. Virgin Islands Banking, Insurance & Financial Regulation
- U.S. Virgin Islands Casino Control Commission
- U.S. Virgin Islands Department of Licensing and Consumer Affairs
- U.S. Virgin Islands Real Estate Commission
- U.S. Virgin Islands Virgin Islands Office of the Lieutenant Governor
- UK Advertising Standards Authority (ASA)
- UK Advertising Standards Authority (ASA) / Committee of Advertising Practice (CAP)
- UK Advertising Standards Authority (ASA) / Financial Conduct Authority (FCA)
- UK Competition and Markets Authority (CMA)
- UK Competition and Markets Authority (CMA) / Trading Standards
- UK Financial Conduct Authority (FCA)
- UK Financial Conduct Authority (FCA) / Association of British Insurers (ABI)
- UK Financial Conduct Authority (FCA) / Prudential Regulation Authority (PRA)
- UK Information Commissioner's Office (ICO)
- UK Medicines and Healthcare products Regulatory Agency (MHRA)
- UK Medicines and Healthcare products Regulatory Agency (MHRA) / Advertising Standards Authority (ASA)
- UK Parliament (consumer protection); FCA enforcement
- UK Parliament / FCA
- USDA Agricultural Marketing Service (AMS)
- USDA Food Safety and Inspection Service
- USPTO / DOJ EOIR / IRS / State Bars
- UT Department of Commerce — Division of Consumer Protection
- UT Department of Financial Institutions
- UT Department of Health
- UT Division of Securities
- UT Motor Vehicle Enforcement Division
- UT State Board of Pharmacy
- Utah Attorney General
- Utah Department of Alcoholic Beverage Services (DABS)
- Utah Department of Commerce — Office of Artificial Intelligence Policy
- Utah Department of Financial Institutions
- Utah Department of Health and Human Services — Center for Medical Cannabis
- Utah Department of Public Safety
- Utah Division of Consumer Protection
- Utah Division of Occupational and Professional Licensing — Pharmacy
- Utah Division of Real Estate
- Utah Insurance Department
- Utah State Bar
- Utah UT Ins Dept
- VA Board of Pharmacy
- VA Bureau of Financial Institutions
- VA Department of Health
- VA Motor Vehicle Dealer Board
- VA Office of Charitable & Regulatory Programs
- VA State Corporation Commission — Division of Securities and Retail Franchising
- VT Board of Pharmacy
- VT Department of Financial Regulation
- VT Department of Financial Regulation — Securities
- VT Department of Health
- VT Department of Motor Vehicles / Vermont Attorney General
- Varies by State; FDA federal
- Vermont Attorney General
- Vermont Bar Association
- Vermont Board of Pharmacy
- Vermont Department of Financial Regulation
- Vermont Department of Financial Regulation (DFR)
- Vermont Department of Financial Regulation - Insurance Division
- Vermont Department of Financial Regulation — Insurance Division
- Vermont Department of Liquor and Lottery
- Vermont Department of Liquor and Lottery (DLL)
- Vermont Office of the Attorney General
- Vermont Real Estate Commission
- Vermont VT DFR
- Virginia Alcoholic Beverage Control Authority
- Virginia Attorney General
- Virginia Board of Pharmacy
- Virginia Bureau of Financial Institutions
- Virginia Cannabis Control Authority (CCA)
- Virginia Lottery Board
- Virginia Real Estate Board
- Virginia State Bar
- Virginia State Corporation Commission (SCC)
- Virginia State Corporation Commission Bureau of Insurance
- Virginia VA BOI
- WA Department of Financial Institutions
- WA Department of Financial Institutions — Securities
- WA Department of Licensing
- WA Secretary of State
- WA State Board of Pharmacy
- WI Board of Pharmacy
- WI Department of Financial Institutions
- WI Department of Financial Institutions — Division of Securities
- WI Department of Transportation Motor Vehicle Division
- WV Board of Pharmacy
- WV Division of Financial Institutions
- WV Division of Motor Vehicles / West Virginia Attorney General
- WV Securities Commission
- WY Department of Revenue
- WY Department of Transportation
- WY Division of Banking
- WY Secretary of State — Compliance Division
- WY State Board of Pharmacy
- Washington Attorney General
- Washington D.C. Attorney General
- Washington D.C. Department of Insurance, Securities and Banking (DISB)
- Washington D.C. Department of Licensing and Consumer Protection
- Washington D.C. Office of Human Rights
- Washington D.C. Office of Lottery and Gaming
- Washington Department of Ecology
- Washington Department of Financial Institutions
- Washington Liquor and Cannabis Board (LCB)
- Washington Office of the Insurance Commissioner
- Washington Office of the Insurance Commissioner (OIC)
- Washington State Attorney General
- Washington State Bar Association
- Washington State Department of Agriculture
- Washington State Department of Ecology
- Washington State Department of Financial Institutions
- Washington State Department of Licensing
- Washington State Department of Licensing (DOL)
- Washington State Labor and Industries (L&I)
- Washington State Pharmacy Quality Assurance Commission
- Washington WA Dept Labor & Industries
- Washington WA OIC
- West Virginia Attorney General
- West Virginia Board of Medicine
- West Virginia Board of Pharmacy
- West Virginia Division of Financial Institutions
- West Virginia Offices of the Insurance Commissioner
- West Virginia Real Estate Commission
- West Virginia State Bar
- West Virginia WV OIC
- Wine Institute
- Wisconsin Department of Agriculture, Trade and Consumer Protection (DATCP)
- Wisconsin Department of Agriculture, Trade and Consumer Protection (DATCP); UW-Madison Lakeshore Medical
- Wisconsin Department of Financial Institutions
- Wisconsin Department of Financial Institutions (DFI)
- Wisconsin Department of Financial Institutions - Office of Credit Unions
- Wisconsin Department of Revenue
- Wisconsin Department of Safety and Professional Services
- Wisconsin Office of the Commissioner of Insurance (OCI)
- Wisconsin Pharmacy Examining Board
- Wisconsin WI OCI
- Wyoming Attorney General
- Wyoming Attorney General / county prosecutors
- Wyoming Department of Insurance
- Wyoming Division of Banking
- Wyoming Gaming Commission
- Wyoming Insurance Department
- Wyoming Real Estate Commission
- Wyoming State Banking Commissioner
- Wyoming State Bar
- Wyoming WY Ins Dept
- Wyoming WY Workforce Services
- X Corp.
- Yukon Department of Community Services — Consumer Services
- Yukon Office of the Superintendent of Securities; Yukon Consumer Services